ISRG INTUITIVE SURGICAL INC Insider Trading

SVP Jeddi sold 5,625 ISRG shares at $420.55 via 10b5-1 plan; retains 6,463 shares post-sale

Iman Jeddi, SVP & General Manager of da Vinci Platforms, sold 5,625 shares (5.6K shares) for $2,365,593.75 ($2.4M) on 2026-06-01 under a pre-arranged 10b5-1 trading plan. The sale reduced his non-derivative holdings from 12,088 to 6,463 shares, representing a 46.5% reduction in that position. This is a scheduled, non-discretionary transaction, meaning the timing and execution were determined in advance and not a reflection of current market conditions or conviction. The stock has declined 33.7% from its 52-week high of $603.88 and is currently trading at $400.40, down 12.5% over 30 days and 20.1% over 90 days—context that shapes but does not alter the mechanical nature of the 10b5-1 plan. Given ISRG's strong fundamentals (revenue growth of 20.5% YoY, net income of $821.5M, and a market cap of $141.8B), the sale reflects execution of a pre-planned liquidity management plan rather than a discretionary reassessment of the company's prospects.

SVP Mark Brosius sold 3,658 ISRG shares across 3 days (Mar 3-5) for $1,815,061.50; holdings fell 55.7%

Mark Brosius, SVP & Chief Manufacturing and Supply Chain, executed 3 separate sales totaling 3,658 shares for $1,815,061.50 over three consecutive trading days (March 3–5, 2026) at prices ranging from $488.10 to $498.68, reducing his holdings by 55.7% from 6,564 to 2,906 shares. The blended average sale price of $496.19 sits very close to the current price of $496.70, indicating no material divergence between execution and present valuation. Across his same-ticker history at ISRG, prior sells have not demonstrated well-timed exits—0 of 3 measurable 90-day outcomes show a decline following the sale, suggesting the stock has tended to rise after his prior dispositions at this company. Without a disclosed schedule or plan FLAG, the multi-day spacing and volume of this sale warrant scrutiny against seasonal liquidity or equity-plan vesting, though no such context is provided in the filing.

ISRG Chief Medical Officer sells 4,853 shares (92.2% of holdings) across 2 transactions for $2,364,960.79

Myriam Curet, EVP & Chief Medical Officer, executed 2 separate sales totaling 4,853 shares for $2,364,960.79, reducing her holdings from 5,262 shares to 409 shares (92.2% reduction). Her same-ticker sales history shows a strong pattern: 4 of 4 prior sells at ISRG were well-timed at the 90-day mark, with negative 90-day returns after the sales. However, the cross-ticker track record shows her sells average +1.4% 30-day return and +3.0% 90-day return with a 47.06% well-timed rate, indicating mixed timing ability across other stocks. The stock currently trades at $497.42, down 1.4% over 30 days and down 12.7% over 90 days, and is down 16.1% from its 52-week high of $592.85. The company shows robust fundamentals: $2,505,100,000 quarterly revenue with 20.5% annual growth and $704,400,000 net income, though the P/E of 53.83 reflects a premium valuation. The scale of this sale—reducing her stake to 409 shares—merits attention given her C-suite medical leadership role, though the transaction does not definitively signal material adverse information absent additional context.

Director Gary Guthart sold 27,300 ISRG shares for $14,475,672.47 via scheduled 10b5-1 plan

Director Gary Guthart executed 3 separate sales totaling 27,300 shares for $14,475,672.47 on 2026-01-27 at a blended average price of $530.24 per share, reducing his holdings from 43,020 shares to 15,720 shares (a 63.5% reduction in position). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than discretionary. As a scheduled sale under a pre-established plan, the timing reflects plan execution rather than market conditions or conviction signals. The substantial reduction in holdings reflects the mechanical execution of a previously committed trading schedule.

Brosius (SVP Mfg/Supply Chain) sells 4,964 shares for $2.7M via 10b5-1 plan; 443 shares remain.

Brosius, SVP & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, executed 2 separate sales totaling 4,964 shares for $2,717,619.36 under a pre-arranged 10b5-1 trading plan. His holdings dropped from 5,407 shares to 443 shares post-transaction. The transactions were scheduled and non-discretionary under the 10b5-1 mechanism, meaning the timing and pricing reflect pre-planned execution rather than current market judgment. The near-complete divestiture of his ISRG position warrants attention to whether this reflects changes in his role, diversification strategy, or other personal circumstances unrelated to company outlook.

GUTHART GARY S sells 22,806 shares of ISRG for $13.0M under pre-arranged 10b5-1 plan; holdings reduced to 2.7K shares

GUTHART GARY S, Executive Chair of the Board, executed a sale of 22,806 shares at $570.89 on 2025-12-01 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 25,500 shares to 2,694 shares. The sale represents a -89.4% reduction in pre-transaction holdings. Since this transaction is scheduled under a 10b5-1 plan, it reflects a contractual obligation entered into at an earlier date rather than a discretionary trade decision made at the time of execution. The substantial reduction in the Executive Chair's direct share ownership is a structural change in leadership holdings that may be of interest to investors monitoring insider position levels.

EVP Charlton sells 13,731 shares ($7,963,980.00) in 5 transactions at $580.00 on 2025-11-12, reducing holdings 81.8%

Charlton Henry L, EVP & Chief Commercial and Marketing, executed 5 separate sales totaling 13,731 shares for $7,963,980.00 at $580.00 per share on November 12, 2025, reducing his holdings from 16,787 to 3,056 shares (an 81.8% reduction). The transaction occurred near the company's 52-week high of $610.45 and above the current price of $565.51. His prior 5 sales at ISRG all occurred on 2024-08-23 and registered negative or neutral 30-day returns; across his cross-ticker selling track record, the average 90-day return after sales was +13.1% with a 0.00% well-timed rate, indicating his prior sales have not preceded stock declines. At Intuitive's current valuation of 72.97 P/E and $200.5B market cap, with FY revenue growth of 17.2% and net income of $704.4M, the transaction's timing and magnitude relative to historical patterns and near-peak pricing warrant observation for investor context.

EVP Brian Edward Miller sells 3,500 ISRG shares at $575.00 (2 transactions totaling $2,012,500.00)

Miller executed two separate sales totaling 3,500 shares at $575.00 on 2025-11-10, reducing his holding by -37.8% to 5,758 shares post-transaction. The transaction price of $575.00 sits near the current price of $572.45 and within the 52-week trading range ($429.59–$610.45); ISRG is -6.2% from its 52-week high. Across his prior five sales at ISRG, none generated negative 90-day returns—all showed positive returns, indicating a pattern of selling before appreciation rather than before declines. The stock has appreciated +31.4% over the past 30 days and +20.0% over 90 days, and Miller's cross-ticker track record shows 7 prior sells with an average 90-day return of +9.4% and a 0.00% well-timed rate, suggesting this insider has not historically sold ahead of material downturns.

ISRG VP Fredrik Widman sells 2,067 shares for $1,136,850, reducing holdings 81.4% to 473 shares

Widman executed 2 separate sales totaling 2,067 shares for $1,136,850.00 at $550.00 per share on 2025-11-05, a significant reduction of his holdings by 81.4% from the pre-transaction level of 2,540 shares. The sales occurred near the 52-week range, at prices within 9.9% of the 52-week high of $610.45. His prior three ISRG trades (all on 2024-03-15) each showed positive 90-day returns of +6.5%, meaning subsequent stock appreciation after his prior sales—indicating those prior sales were poorly timed from a timing perspective. His cross-ticker track record shows 3 prior sells with an average 90-day return of +6.5% and a 0.00% well-timed rate, revealing a pattern where his sell signals have not preceded declines. The stock is trading at $547.78, up 24.2% over 30 days and up 16.5% over 90 days, suggesting strong recent momentum near current transaction prices.

Chief Medical Officer Curet sells all 7,687 shares for $4,215,067.88 via scheduled 10b5-1 plan

Myriam Curet, EVP & Chief Medical Officer at Intuitive Surgical, executed 4 separate sales totaling 7,687 shares for $4,215,067.88 at a blended average price of $548.34 on October 28–29, 2025. The transaction represents a complete liquidation of her holdings, with zero shares retained post-sale. Because this sale is part of a pre-arranged 10b5-1 trading plan, it was scheduled rather than discretionary, meaning timing and motivation cannot be inferred from market conditions or stock performance. The material nature of a 100% portfolio exit by a C-suite medical officer warrants investor attention to any contemporaneous company announcements, though the scheduled nature of the plan limits what can be concluded about conviction or forward outlook.